

**April 27, 2023**

**Contents**

Clinical Profile Documentation ..... 2

    AJCC 8th Edition Staging ..... 2

    AJCC 9th Version Staging ..... 2

Lab Analytes & Panels ..... 3

    Additions ..... 3

Medications ..... 3

    Additions ..... 3

    Updates ..... 4

Regimen Library ..... 5

    Additions ..... 5

    Updates ..... 6

Research ..... 7

    Updates ..... 7

Billing & HCPCS Codes ..... 7

    Updates ..... 7

NDC & HCPCS Crosswalk ..... 8

    Updates ..... 8

# Clinical Profile Documentation

## AJCC 8th Edition Staging

This release contains updates to align with the Cotswold modification of the Ann Arbor system to the Lugano Classification system for the following problem groups:

- Lymphoma, Non-Hodgkins (NHL), Other

The staging row will display updated **Stage** values based on the changes. The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

The following documentation points are now available:

- I
- IE
- II
- IIE
- II bulky\*
- III
- IV
- Unknown

## AJCC 9th Version Staging

This release contains updated **TNM** values, **Staging Groups**, and **Template** functionality to align with AJCC version 9 conditions for:

- Malignant, Thymoma

Users will see updated values and descriptions for **Primary Tumor Type (T)**, **Regional Lymph Nodes (N)**, and **Distance Metastasis (M)**, documentation points.

The staging calculator will display updated **Stage** values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

# Lab Analytes & Panels

## Additions

- Alder (T2), IgE
- Allergen Region 17 respiratory IgE panel
- Alternaria alternata (M6), IgE
- Amph/Methamphetamine, urine, qual
- Anaerobic and Aerobic wound culture and gram stain
- APTT mixing study panel
- Ash, white (T15), IgE
- Aspergillus fumigatus (M3), IgE
- ATP1B1
- Birch tree, IgE
- BK virus DNA, quant PCR, plasma, IU/mL
- Cat epithelium/dander (E1), IgE
- CBC w/Auto Diff/ IPF w/ Reflex
- CBC w/Auto Diff/ IPF w/OUT Reflex
- Cedar, mountain (T6), IgE
- Coag consult level limited
- Cockroach, German, IgE
- Cottonwood tree (T14), IgE
- D. farinae mite (D2), IgE
- D. pteronyssinus (D1), IgE
- Dog dander (E5), IgE
- Elm tree, IgE
- Hormodendrum hordei, IgE
- Immunoglobulin E
- Lymphocyte subset panel 4 information
- Maple/Box elder (T1), IgE
- Mouse epithelium, IgE
- Mucor racemosus (M6), IgE
- Nettle (W20), IgE
- Oak tree (T7), IgE
- P. notatum, IgE
- Pigweed, IgE
- POC INR
- POC protime
- PTT 1Hr 1:1 mix, sec
- PTT 1Hr undiluted, sec
- PTT immed 1:1 Mix, sec
- PTT immed undil, sec
- PTT mix study interpretation
- Ragweed, short/common (W1), IgE
- Reticulocyte count method
- RPR monitoring
- RPR monitoring panel
- Sheep sorrel (W18), IgE
- Stool culture micro number
- Stool culture source
- Stool culture specimen quality
- Stool culture status
- Syphilis Ab, IGG IGM serum, qual
- Timothy grass (G6), IgE
- Varicella zoster virus DNA, RT-PCR, quant
- Venous thrombosis evaluation consultation level
- Venous thrombosis evaluation interpretation
- Walnut tree (T10), IgE
- Weekend CBC w/Auto Diff w/ Reflex
- Weekend CBC w/Auto Diff w/OUT Reflex

## Medications

### Additions

- Azeliragon invest Oral
- Iberdomide invest Oral
- Isatuximab invest Subcutaneous (via wearable injector)
- Narazaciclib invest (ON 123300 invest Oral)
- Semaglutide-Cyanocobalamin Subcutaneous

## Updates

Medication	Update
Bendamustine IV	<p><b>New Quick Sigs:</b></p> <ul style="list-style-type: none"> <li>• 0 mg/m<sup>2</sup> intravenously Piggyback once; Dilute in 250 mL NS or D2.5/0.45NS to a final concentration of 0.1-1.36 mg/mL. Administer over 20 minutes. Bendamustine is a vesicant. NOTE: This is Vivimusta.</li> <li>• 0 mg/m<sup>2</sup> intravenously Piggyback once; Dilute in 50 mL NS, D5W, or D2.5/0.45NS to a final concentration of 0.49-5.6 mg/mL. Administer over 10 minutes. Bendamustine is a vesicant. NOTE: This is Bendeka.</li> <li>• 0 mg/m<sup>2</sup> intravenously Piggyback once; Dilute in 500 mL NS or D2.5/0.45NS to a final concentration of 0.05-0.7 mg/mL. Administer doses less than or equal to 100 mg/m<sup>2</sup> over 30 minutes; administer doses greater than 100 mg/m<sup>2</sup> over 60 minutes. Bendamustine is a vesicant. NOTE: This is Belrapzo.</li> <li>• 0 mg/m<sup>2</sup> intravenously Piggyback once; Dilute in 500 mL NS or D2.5/0.45NS to a final concentration of 0.2-0.6 mg/mL. Administer doses 100 mg/m<sup>2</sup> or less over 30 minutes and doses greater than 100 mg/m<sup>2</sup> over 60 minutes. Bendamustine is a vesicant. NOTE: This product is equivalent to Treanda.</li> </ul>
Bendamustine invest IV	Excluded from end-user search
Desmopressin IV	<p><b>New max single dose:</b> 20 mcg</p> <p><b>New quick sigs:</b></p> <ul style="list-style-type: none"> <li>• Desmopressin 0.3 mcg/kg intravenously Piggyback once</li> <li>• Desmopressin 0.3 mcg/kg intravenously Piggyback once; administer over 15-30 minutes; admixture fluid 50 mL</li> </ul> <p><b>New instructions:</b> For Hemophilia A and Von Willebrand's Disease: If used preoperatively, administer 30 minutes prior to procedure. If used to reduce spontaneous or traumatic bleeding, doses may be repeated after 8 to 12 hrs. and once daily thereafter, if needed, based on clinical condition of the patient and laboratory response.</p>

Medication	Update
Etoposide IV	<p><b>Removed instructions:</b></p> <ul style="list-style-type: none"> <li>IVPB: Dilute in 500 mL NS or in sufficient volume of NS to maintain final concentration of less than 0.4 mg/mL. Rate: at least 60 minutes. Use a 0.22 micron in-line filter for concentrations above 0.4 mg/mL. Check for precipitate prior to infusing. Etoposide is an irritant.</li> <li>IVPB (Etoposide phosphate): Dilute in NS based on final concentration. Rate: over at least 30 minutes. Protect from light. Etoposide phosphate is an irritant.</li> <li>CIV: Dilute in NS (CADD); Rate per cited reference; via ambulatory pump. Refer to drug stability guidelines for chemotherapy agent. Etoposide is an irritant.</li> </ul> <p><b>New sigs:</b></p> <ul style="list-style-type: none"> <li>100 mg/m<sup>2</sup> intravenously Piggyback once; Dilute in NS or D5W to achieve a final concentration less than 0.4 mg/ml. Use a 0.22 micron in-line filter for concentrations above 0.4 mg/ml. Check for precipitate. Administer over at least 60 minutes. Use non-DEHP products. Etoposide is an irritant.</li> <li>100 mg/m<sup>2</sup> intravenously Piggyback once; Etoposide PHOSPHATE: Dilute in NS or D5W to a minimum concentration of 0.1 mg/mL. Check for precipitate and discoloration prior to infusing. Administer over 5 to 210 minutes. Etoposide phosphate is an irritant.</li> </ul>
Sacituzumab Govitecan-hziy IV	<p><b>New max single dose:</b> 1500 mg</p> <p><b>New instructions:</b> Dilute in NS to a final concentration of 1.1 to 3.4 mg/mL in a PVC, PP/PE, PO, or EVA infusion bag. Do not freeze. Do not shake. Protect from light. First infusion: Administer over 3 hours. Subsequent infusions: Administer over 1 to 2 hours if prior infusions were tolerated. Do not administer IV push or bolus. Do not mix or infuse with other drugs. Observe patient for signs or symptoms of infusion-related reactions during each infusion and for at least 30 minutes after each infusion. Flush with 20 mL NS following infusion.</p>

## Regimen Library

### Additions

Regimen Name	Diagnosis
Bendamustine D1,2 Q28D (Waldenstroms)	Waldenstrom's Macroglobulinemia
Cisplatin D1,22 + XRT Q42D fb Paclitaxel + Carboplatin Q21D (Part 1 of 2)	Uterine Cancer (Parent)

Cisplatin D1,22 + XRT Q42D fb Paclitaxel + Carboplatin Q21D (Part 2 of 2)	Uterine Cancer (Parent)
Darbepoetin alfa Q7D (Myelofibrosis) Supportive Care	Myelofibrosis
Enfortumab vedotin-ejfv D1,8 + Pembrolizumab Q21D	Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer
Epoetin alfa Q7D (Myelofibrosis) Supportive Care	Myelofibrosis
Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (Waldenstroms)	Waldenstrom's Macroglobulinemia
Fludarabine D1-5 + Rituximab IV Q28D	Waldenstrom's Macroglobulinemia
Lusutrombopag	All Problems
Retifanlimab-dlwr Q28D	Merkel Cell Carcinoma
Rituximab IV + Ixazomib D1,8,15 + Dexamethasone Q28D fb Q56D	Waldenstrom's Macroglobulinemia
Rituximab IV D2 + Carfilzomib D1,2 + Dexamethasone Q56D (Part 2 of 2: Maintenance)	Waldenstrom's Macroglobulinemia
Rituximab IV D2,9 + Carfilzomib D1,2,8,9 + Dexamethasone Q21D (Part 1 of 2: Induction)	Waldenstrom's Macroglobulinemia
Rituximab IV D1,8,15,22 Q84D	Waldenstrom's Macroglobulinemia
Rituximab IV + Cladribine SQ D1-5 Q28D (Waldenstroms)	Waldenstrom's Macroglobulinemia
Rituximab IV + Cyclophosphamide PO D1-5 + Dexamethasone Q21D	Waldenstrom's Macroglobulinemia
Rituximab IV + Cyclophosphamide + Prednisone Q21D	Waldenstrom's Macroglobulinemia
Venetoclax Q30D (Waldenstroms)	Waldenstrom's Macroglobulinemia

## Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Anal Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cancer of Unknown Primary
- Cervical Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Kaposi's Sarcoma
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Melanoma, Skin
- Ovarian and Primary Peritoneal Cancer
- Renal Pelvis and Ureter Cancer
- Testicular Cancer (Parent)
- Urethral Cancer
- Uterine Cancer (Parent)

## Research

### Updates

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 20208	X	X		
USOR 21173	X			
USOR 21228	X	X	X	
USOR 21326	X		X	
USOR 21356	X	X		Now available: USOR 21356 Optional Maintenance Mosunetuzumab SC Q56D
USOR 21498	X	X	X	
USOR 21527	X	X	X	
USOR 21546	X			
USOR 22003	X			
USOR 22042	X	X		
USOR 22049	X	X	X	
USOR 22107	X	X	X	

## Billing & HCPCS Codes

### Updates

Medication	HCPCS Codes
Acetaminophen IV	J3490 per 1000 mg
Bevacizumab-adcd IV (Vegzelma)	Q5129 per 10 mg
Carmustine IV	J3490 per 100 mg
Furosemide	J3490 per 20 mg
Glycopyrrolate	J3490 per 0.2 mg
Retifanlimab-dlwr IV (Zynyz)	J3590 per 500 mg

Medication	HCPCS Codes
Varicella Virus Vaccine Live (PF) (Varivax)	90749 per 0.5 mL
Vilobelimab IV (EUA) (Gohibic)	J3590 per 200 mg

## NDC & HCPCS Crosswalk

### Updates

Medication	HCPCS Code	NDC
Acetaminophen IV	J3490 per 1000 mg	00143938601 00143938610
Carmustine, IV	J3490 per 100 mg	16729054305 16729054563 16729054601 16729054863
Furosemide	J3490 per 20 mg	81565020102 81565020101
Camcevi (Leuprolide Subcutaneous (6 month))	J1952 per 1 mg	169448001463